Presentation is loading. Please wait.

Presentation is loading. Please wait.

Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA.

Published byMerilyn Oliver Modified over 8 years ago

Similar presentations

Presentation on theme: "Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA."— Presentation transcript:

1 Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA

2 Presentation Outline Regulatory background Past endpoints in Oncology Approvals for colon cancer (adjuvant, first- line and second-line therapy) Studies supporting drug approval Endpoints supporting approval in CRC

3 Requirements for Drug Approval Safety (FDAC, 1938) Efficacy demonstrated in adequate and well controlled studies (1962) Basis for efficacy: –Regular approval Clinical benefit, or Established surrogate for clinical benefit –Accelerated approval Surrogate (reasonably likely to predict CB)

4 How many trials? Usually more than one trial is needed. Substantial evidence: “Adequate and well-controlled investigations” Sometimes a single trial may suffice. –FDAMA (1997) single trial + other supportive evidence –1998 FDA Effectiveness Guidance: Multicenter trial Statistically strong evidence Important clinical benefit Additional trials not ethical

5 Regular Approval Endpoints in Oncology

6 Clinical Benefit Endpoints Survival Improvement in tumor-related symptoms

7 Established Surrogates Disease-free survival (selected settings) Complete response rates in some settings (e.g., acute leukemia) Partial response rate in some settings (e.g., hormonal treatment of breast cancer)

8 Endpoints other than Survival Approvals not based on Survival (From 1/1/90 - 11/1/02 )) : –73% (48/66) of all approvals –67% (37/55) excluding accelerated approvals

9 Accelerated Approval (AA) Serious or life-threatening disease Drug must provide benefit over available therapy Surrogate endpoint may be used Surrogate endpoint must be reasonably likely to predict clinical benefit Post marketing studies must verify clinical benefit

10 Agents Approved AdjuvantFirst-LineRefractory Levamisole (+ 5FU) 1990 -Leucovorin (with 5FU) 1991 -Irinotecan (+ 5FU/LV) 2000 -Capecitabine 2001 -Oxaliplatin (+ 5FU/LV) 2004 -Bevacizumab 2004 -Irinotecan 1996,1998 -Oxaliplatin (+ 5FU/LV) 2002 -Cetuximab 2004

11 Historical Endpoints for Approval OS TTP & RR Superiority Noninferiority

12 Agents for Adjuvant Therapy

13 Levamisole (Adjuvant Rx) ArmsN Follow up (Yrs) Reduction in Recurrence % Reduction in Death % Study 1 Duke C Subset 5FU+lev 2625 3627 lev28 Observe Study 2 5FU+lev 9292 4133 lev26 Observe

14 Agents for First-line Therapy

15 5FU+leucovorin (First-line Rx) StudyArmsN RR % TTP mo OS mo P (one-sided) 1 5FU70102.97.7 5FU+LV(HD)69266.712.20.04 5FU+LV(LD)73446.7120.05 2 (Study 1 ext) 5FU+LV(HD)1493112.70.04 5FU+LV(LD)1534212.70.01 5FU+MTX+LV155148.4

16 Irinotecan (First-line Rx) StudyArmsNRRTTPOS P (one-sided) 1 CPT 11 wkly x 4 (q 6 wks) 226184.212 CPT11 + 5FU/LV wkly x 4 (q 6 wks) 23139714.8 <0.05 5FU/LV qd x 5 (q 6 wks) 226214.312.6 2 CPT11 + inf 5FU/LV 198356.717.4 <0.05 5FU/LV187224.414.1

17 Capecitabine (First-line Rx) StudyArmsN RR (%) TTP (mo.) OS (mo.) Hazard ratio 1 Cap302214.312.7 1.00 0.84 – 1.18 5FU/LV303114.413.6 2 Cap301214.613.5 0.92 0.78 – 1.09 5FU/LV301144.412.3

18 Oxaliplatin (First-line Rx) StudyArmsNRR*TTP*OSHR for OS 1 IFL264336.914.6 0.65 (0.53-0.8) FOLFOX4267458.719.4 IROX264356.517.6 * RR and TTP based on unblinded investigator assessment

19 Bevacizumab (First-line Rx) StudyArmsN RR (%) PFS (mo.) OS (mo.) HR for OS 1 IFL411356.415.6 0.66 IFL + Bev4024510.620.3 2 5FU/LV36175.2*13.6 5FU/LV + Bev (5mg) 35409*17.7 5FU/LV + Bev (10 mg) 33247.215.2 * Comparison statistically significant for Study 2

20 Agents for Refractory Cancer

21 Irinotecan (Refractory; AA) StudyArmsN RR (%) TTP (mo.) OS (mo.) Med Resp Duration 1Wkly CPT 1148216.410.4 5.8 mo. (2.6-15.2) 2Wkly CPT 1190135.98.1 3 Wkly CPT 11 125 mg/m 2 64145.610.7 Wkly CPT 11 100 mg/m 2 10296.49.3

22 Irinotecan (Refractory; reg. approval) StudyArmsN OS (mo.) p 1 CPT 111899.2 0.0001 Best Supportive Care 906.5 2 CPT 1112710.8 0.035 5FU-based regimens 1298.5

23 Oxaliplatin (Refractory; AA) StudyArmsN RR (%) TTP (mo. with 95% CI) P for RR 1 Oxaliplatin + 5FU/LV (FOLFOX4) 1529 4.6 (4.2 – 6.1) 0.0002 5FU + LV1510 2.7 (1.8-3.0) Oxaliplatin1561 1.6 (1.4-2.7)

24 Cetuximab (Refractory; AA) StudyArmsN RR (%) TTP (mo) HR 1 CPT-11 + Cet 21822.94.1 0.54 (0.42-0.71) Cet 11110.81.5 2 CPT-11 + Cet 13815 3 Cet 579

25 Summary of FDA Requirements FDA requirements –Evidence from Trials or Trial+ –RA: Clinical Benefit or accepted surrogate –AA: Advantage over available therapy with regard to a “reasonably likely surrogate”

26 Basis of Approval Adjuvant Therapy (1 reg approval) Superiority in Survival (1) First-line Therapy (5 reg approvals) Superiority in Survival (4) Non-inferiority in Survival (1) Therapy for Refractory Disease (3 AA, 1 reg) Survival (1 reg for CPT-11) RR and/or TTP (3 AA)

Download ppt "Regulatory Background and Past FDA Approvals in Colorectal Cancer Amna Ibrahim M.D DODP, FDA."

Similar presentations

Oncologic Drugs Advisory Committee

Oncologic Drugs Advisory Committee
CM923700-1 A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.

CM A pooled safety & efficacy analysis examining the effect of performance status on outcomes in 9 first line treatment trials of 6,286 patients.
Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.
MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize. DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% FOLFOX.

MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize. DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% FOLFOX.
A Phase III Trial Comparing FULV to FULV + Oxaliplatin in Stage II or III Carcinoma of the Colon: Results of NSABP-C-07 Norman Wolmark, MD Colorectal Cancer.

A Phase III Trial Comparing FULV to FULV + Oxaliplatin in Stage II or III Carcinoma of the Colon: Results of NSABP-C-07 Norman Wolmark, MD Colorectal Cancer.
Accelerated Approval Update 2005 Ramzi Dagher, MD DDOP/OODP/CDER/FDA.

Accelerated Approval Update 2005 Ramzi Dagher, MD DDOP/OODP/CDER/FDA.
D. Haller, CRC Symposium, 1.23.2001 Oncology Spectrums, NYC Combination and Sequential Chemotherapy of Metastatic Colorectal Cancer Daniel G. Haller, MD.

D. Haller, CRC Symposium, Oncology Spectrums, NYC Combination and Sequential Chemotherapy of Metastatic Colorectal Cancer Daniel G. Haller, MD.
1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.

1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,

Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent trials settled the question of maintenance versus observation in advanced CRC? Yes Deborah Schrag,
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.

Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
Defining Success in Oncology Drug Development Richard Pazdur, MD CDER, FDA The views expressed are the results of independent work and do not necessarily.

Defining Success in Oncology Drug Development Richard Pazdur, MD CDER, FDA The views expressed are the results of independent work and do not necessarily.
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Selected Issues in Oncology Trial Design Grant Williams, M.D. DODP, CDER, FDA.

Selected Issues in Oncology Trial Design Grant Williams, M.D. DODP, CDER, FDA.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Drug Treatment of Metastatic Breast Cancer

Drug Treatment of Metastatic Breast Cancer
Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.

Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.
1 Stage III Colon Cancer What Works? Thierry André, MD Medical Oncology Departement, Hôpital Saint Antoine, APHP, Paris, France and University Pierre et.

1 Stage III Colon Cancer What Works? Thierry André, MD Medical Oncology Departement, Hôpital Saint Antoine, APHP, Paris, France and University Pierre et.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.

Similar presentations

Ads by Google